Miniaturisation Techniques for Dose Optimisation of Chemotherapeutic Agents (miniDOC)

作为一名创新学者，**Anand Pallipurath Radhakrishnan（APR）** 将迅速从伦敦大学学院（UCL）电化学创新实验室（EIL）过渡到与主办公司 **Vesynta Ltd.** 合作，标志着一种新的知识交流伙伴关系。** 由UCL领导的miniDOC项目 ** 将由Vesynta与多机构学术合作伙伴和NHS临床医生合作，所有 ** 的共同目标是开发一种迫切需要的即时药物监测设备乳腺癌治疗 **。APR将扩大他的技术技能，以推进智能工程解决方案 ** 从实验室到医疗保健环境中的患者床边 **，在此过程中满足长期的职业抱负。严格的设备原型设计，可扩展的制造技术，体外诊断法规要求，机器人自动化和临床试验设计，只是APR将通过miniDOC项目配备的一些技能。此外，Vesynta的核心优势，如个性化医疗和监测，设备制造和原型设计，患者样本的获取以及强大的临床和学术合作伙伴网络，将被利用来显着提高APR的专业形象。** 职业流动性是设想的，因为APR将在借调期结束前被考虑在Vesynta** 内担任研发技术主管。这进一步加强了成功产品开发管道的实施，并真正支持设备在护理点的部署。** 将寻求UCL医疗工程研究所的指导和指导 **，以确保监控项目目标并管理相关风险。同时，这种合作关系将利用APR在微流体工程，先进的计算图像分析和生物技术创新方面的技能，以解决Vesynta面临的挑战。在借调期间，**APR将促进UCL和Vesynta之间的创新思想的交叉授粉，寻求生物分析传感研究的新途径 ** 进一步提高EIL在电化学分析方面的专业知识。已经制定了具体的，可衡量的和可实现的目标，以挖掘APR的技术潜力，并利用Vesynta的核心优势，同时加速开发支持个性化医疗实践的平台。** miniDOC项目的成功交付有可能对癌症患者的治疗结果产生重大影响。**通过采用安全有效的个性化药物监测实践，针对乳腺癌成人患者进行精确给药，** miniDOC项目不仅将对医疗保健部门产生直接影响，还将对经济产生直接影响。

As an Innovation Scholar, **Anand Pallipurath Radhakrishnan (APR)**, would swiftly transition from University College London (UCL) Electrochemical Innovations Lab (EIL) to work with the host company, **Vesynta Ltd.**, marking a new knowledge exchange partnership. **The miniDOC project**, led by UCL, will be partnered by Vesynta with additional input from multi-institutional academic partners and NHS clinicians, all **with a common goal of developing a point-of-care drug monitoring device with a pressing need in breast cancer therapy**.In pursuit of developing a dose optimising blood test device, APR will broaden his technical skills to advance smart engineering solutions **from a laboratory to the patient bedside in a healthcare setting**, satisfying a long-term career aspiration in the process. Rigorous device prototyping, scalable manufacturing techniques, _in vitro_ diagnostic regulatory requirements, robotic automation, and clinical trial design, are but a few skills APR would be equipped with through the miniDOC project. Additionally, Vesynta's core strengths, such as personalised medicine and monitoring, device manufacturing and prototyping, access to patient samples and a strong network of clinical and academic partners, will be exploited to significantly enhance APR's professional profile. **Career mobility is envisioned as APR will be considered for a Research and Development Technical Lead role within Vesynta** by the end of the secondment period. This further strengthens the implementation of a successful product development pipeline and truly supports the deployment of the device at the point-of-care. **Guidance and mentorship will be sought from UCL Institute of Healthcare Engineering** to ensure monitoring of the program objectives and to manage the associated risks.Simultaneously, this partnership shall leverage APR's skills in microfluidic engineering, advanced computational image analysis and biotechnology innovation, to solve challenges faced by Vesynta. During the secondment, **APR will facilitate cross-pollination of innovative ideas between UCL and Vesynta, seeking new avenues of research into bioanalytical sensing** furthering EIL's expertise in electrochemical analysis.Specific, measurable and achievable objectives have been drawn out to elicit APR's technical potential and to exploit Vesynta's core strengths, whilst accelerating the development of a platform that supports the practice of personalised medicine. **The successful delivery of the miniDOC project has the potential for a high impact on the treatment outcomes of cancer patients.** Through the adoption of safe and effective personalised drug monitoring practices with precision dosing aimed at adults with breast cancer, **the miniDOC project will make a direct impact on not only the healthcare sector but also on the economy**.